Altimmune’s 2025 Q1 Results Highlight Clinical Progress

Altimmune ( (ALT) ) has released its Q1 earnings. Here is a breakdown of the information Altimmune presented to its investors.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases, with its lead program being pemvidutide, a GLP-1/glucagon dual receptor agonist.

In its first quarter 2025 earnings report, Altimmune highlighted significant progress in its clinical trials and financial positioning. The company is on track to release top-line data from its IMPACT Phase 2b trial of pemvidutide for MASH in the second quarter of 2025 and plans to initiate Phase 2 trials for AUD and ALD later in the year.

Key financial metrics for the quarter include cash, cash equivalents, and short-term investments totaling $150 million, and a secured $100 million credit facility with Hercules Capital to bolster financial flexibility. The company reported a net loss of $19.6 million, an improvement from the $24.4 million net loss in the same period last year, attributed to reduced research and development expenses.

Strategically, Altimmune is expanding the potential applications of pemvidutide, with new trials set for AUD and ALD, both areas with significant unmet medical needs. The company’s financial health is reinforced by its credit facility, which provides additional resources for its ongoing and future clinical developments.

Looking ahead, Altimmune remains focused on advancing its clinical programs and achieving key milestones in 2025, with an emphasis on leveraging pemvidutide’s unique clinical profile to address liver and cardiometabolic diseases.